Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned an average recommendation of “Hold” from the five research firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $13.75.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Tuesday, February 25th.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the completion of the sale, the senior vice president now owns 309,565 shares in the company, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Theravance Biopharma

A number of hedge funds have recently modified their holdings of TBPH. Barclays PLC increased its position in Theravance Biopharma by 279.9% in the 3rd quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock valued at $529,000 after acquiring an additional 48,316 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Theravance Biopharma by 2.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock valued at $2,151,000 after purchasing an additional 7,620 shares during the last quarter. Algert Global LLC acquired a new position in shares of Theravance Biopharma in the third quarter valued at approximately $851,000. Jane Street Group LLC raised its stake in shares of Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after purchasing an additional 1,640 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Theravance Biopharma by 88.9% during the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after purchasing an additional 143,781 shares during the period. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Trading Down 0.9 %

Shares of NASDAQ TBPH opened at $9.23 on Friday. The stock has a market cap of $456.62 million, a P/E ratio of -9.14 and a beta of 0.15. The business’s fifty day simple moving average is $9.40 and its 200-day simple moving average is $9.09. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million. On average, equities analysts forecast that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.